This suggests a 72% lower risk of mild cognitive impairment-like symptoms when taking medication (RR = 0.28) however, the effect was not significant. One of the patients taking medication scored below the threshold compared to six of those not taking medication. Of the 24 patients with ADHD, 9 (37.5%) were taking medication at the time of testing.
The risk of scoring in the mild cognitive impairment range for those with and without ADHD was equal (RR = 0.98). Seven (29.2%) of those with ADHD scored below the threshold. Of the 105 participants without ADHD, 31 (29.5%) scored below the threshold. Of the 129 participants included in the analyses, 38 (29.5%) scored below the MoCA threshold (< 26), and 24 (18.6%) had ADHD that was diagnosed before or during the inpatient treatment. Finally, we calculated the RR for the patients within the ADHD group who were taking medication. We calculated relative risk estimates (RR) for scoring in the mild cognitive impairment range (< 26) for those having ADHD. The participants in this study were 129 inpatients at seven treatment clinics in Norway. Second, we assessed the impact of ADHD medication on the dichotomized MoCA for patients with ADHD. We wanted to investigate whether patients with ADHD have an excess risk of mild cognitive impairment-like symptoms, as defined by the Montreal Cognitive Assessment (MoCA). Attention-deficit/hyperactivity disorder (ADHD) frequently co-occurs with substance use disorders and has some overlapping symptoms with mild cognitive impairment, including executive functions.